Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

Eli Lilly, the maker of the popular injectable Mounjaro, has just released the surprising phase 3 trial results for its new ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Eli Lilly & Co. is tapping the US investment-grade debt market with a deal that’s expected to include a 40-year bond, a ...

To provide a brief background, the TRAILBLAZER-ALZ 2 LTE study was a Phase 3, double-blind extension of the original ...

A late-stage trial shows a daily pill helped people lose 12% of their body weight—without injections. Nine teens arrested ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Eli Lilly is planning to significantly hike the price of the weight-loss drug Mounjaro in the United Kingdom in a bid to make it cheaper in the U.S.

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...

Over the past five years, Eli Lilly stock has risen roughly 320% as of market close Aug. 11. Meanwhile, the company has ...